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Abstract
Previously, we have successfully targeted the mannose receptor (MR) expressed on monocyte-
derived dendritic cells (DCs) using a fully human MR-specific antibody, B11, as a vehicle to deliver
whole protein tumor antigens such as the human chorionic gonadotropin hormone (hCGβ). Since
MRs play a role in bridging innate immunity with adaptive immunity we have explored several toll-
like receptor (TLR)-specific ligands that may synergize with MR targeting and be applicable as
adjuvants in the clinic. We demonstrate that antigen-specific helper and cytolytic T cells from both
healthy donors and cancer patients were effectively primed with B11-hCGβ-treated autologous
DCs when a combination of one or several TLR ligands is used. Specifically, concomitant signaling
of DCs via TLR3 with dsRNA (poly I:C) and DC TLR 7/8 with Resiquimod (R-848), respectively,
elicited efficient antigen presentation-mediated by MR-targeting. We demonstrate that MR and
TLRs contribute towards maturation and activation of DCs by a mechanism that may be driven by
a combination of adjuvant and antibody vaccines that specifically deliver antigenic targets to DCs.
Background
Pathogen encounter by cells of the immune system repre-
sents a form of danger initially sensed by professional
antigen presenting cells such as dendritic cells (DCs) that
undergo specialization to prime naïve T and B lym-
phocytes leading to a cellular or humoral response or
both [1-4]. There is substantial evidence that defined
molecular events within DCs follow the biosynthesis of
pro-inflammatory, inflammatory and anti-inflammatory
cytokines/chemokines, notably the up-regulation of MHC
Class I and II as well as co-stimulatory molecules (CD80
and CD86). These changes often promote the develop-
ment of a potent effector T cell or antibody response
needed to eradicate or contain pathogen-invaded tissue
[5,6]. In recent years, several new studies have come forth
that highlight the importance of Toll-like receptors (TLRs)
and the critical role they play in integrating innate immu-
nity with adaptive immunity [7,8]. These novel insights
have provided the scientific and technological impetus for
the burgeoning development and growth of a variety of
strategies that are currently being pursued to target the
TLRs either for inducing tolerance, enhancing immunity
or even reversing autoimmunity [9-15]. Modulation of
DCs ex vivo to achieve some of these goals is now highly
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plausible, resulting in a type of DC that can be effectively
tailored to suit vaccine formulations [16]. There is also a
better understanding of which TLRs to activate in combi-
nation and which to avoid [17-19]. In vivo, however, this
task has remained a major challenge, presumably owing
to poor targeting capabilities and the non-specific action
of TLR activating ligands since similar TLRs also are
expressed in non-antigen presenting cells [20,21]. Conse-
quently, current strategies are limited to creating stable
chemistries to conjugate these ligands to the vaccine of
choice or by employing molecular engineering techniques
to generate fusion protein products (e.g. studies in this
laboratory), adenoviral or similar non-replicating vectors
containing the antigen, CD40L or co-stimulatory mole-
cules [11,22]. Recently, studies using the bacterial outer
membrane protein A, such as KpOmpA (Klebsiella sp.-
derived) or other bacteria-derived products have shown
potent modulation of antigen presentation by DCs medi-
ated via specific TLR molecules [23,24]. While the actions
of these bacterial products and other TLR-specific ligands
induce DC maturation, it must be recognized that not all
modulating agents yield activated DCs which are required
for the development of a classical Th1 immune response
(CTL effector induction accompanied by IL-12p70, TNFα
and IFNγ production) [reviewed in Ref. [8]]. Exploiting
DCs for the purpose of delivering whole protein antigens
while supporting TLR signaling might require that MR and
particular TLRs be spatio-temporarily connected [25].
There is growing evidence from different laboratories
establishing an association between TLRs and C-type lec-
tin receptors (CLRs, such as, mannose receptor (MR), Dec-
tin-1 and DC-SIGN among others) which can shape the
outcome of the response depending on which TLRs and
their adapters are assembled to interface with CLRs
[21,26,27]. In this regard, the mannose receptor plays an
important role in innate immune responses, especially in
maintaining homeostasis and state of tolerance. However,
we and others have successfully shown that endocytic
receptors on DCs can be exploited to deliver exogenous
soluble antigens for effective cross-presentation to T cells
[28] using antibodies to MR [29-31], DEC-205 [32] DC-
SIGN [33], Dectin-1 [34] and TLR2 [35-37]. While there is
availability of synthetic or natural ligands for in vitro and
in vivo studies in small animals, not all agents are suitable
or adequately tested and formulated for human use. In the
present study, we have investigated only those TLR activat-
ing agents which can be made as GMP material for com-
bination with our vaccine candidate, B11-hCGβ.
The tumor-associated antigen, hCGβ, is overexpressed in
a wide variety of human tumors including colorectal, pan-
creatic, bladder, renal, breast and germ cell tumors,
among others [[31,38] and [39]]. Here, we show that DCs
are modulated to prime T cell responses when the expo-
sure to vaccine occurs in the presence of a TLR 3-specific
dsRNA (poly I:C) and a TLR 7/8-specific agent, Resiqui-
mod (R-848). The in vitro induction of primary cell-medi-
ated immune responses to a normally non-antigenic
protein in both normal donors as well as cancer patients
points to DCs being the appropriate APCs for stimulation
of the immune system. Thus the combination of TLR acti-
vation with an MR-targeted vaccine can significantly
improve the therapeutic efficacy of DC-targeted vaccines.
Materials and methods
Human subjects
Peripheral blood from normal healthy volunteers was
procured from a local blood bank (Biological Specialties
Corp., Colmar, PA) or from pancreatic, bladder or colon
cancer patients with informed consent following IRB
approval from Duke University Medical Center, Durham,
NC. The status of hCGβ expression in patient's blood or
tumor was not determined in the patients for this study
although such evidence has previously been documented
in literature [38,39]. All blood products were handled
under aseptic conditions. Leukapheresis of donors typi-
cally yielded 4–5 × 109 total cells, which were subse-
quently enriched for mononuclear cells using density
gradient centrifugation. Cells from each donor were aliq-
uoted at 5 × 107 – 1 × 108/ml before cryopreservation in
liquid nitrogen.
Cell Lines
Two cell lines were used in determining the specificity of
vaccine responses: T2, a TAP-/- T-B hybrid cell line that is
defective in antigen processing and K562, an HLA class I
negative, NK-sensitive human eythroleukemia cell line
(both obtained from ATCC, Manassas, VA). Both cell lines
were maintained in IMDM + 10% FBS supplemented with
2 mM L-Glutamine and 25 µg/ml gentamicin.
TLR agonists and MR targeted vaccines
The following TLR agonists were employed in experi-
ments aimed at simultaneous engagement of TLRs and
MR: R-848 (Resiquimod, 3M Pharmaceuticals, St. Paul,
MN), a small molecule immunomodulator specific for
human TLR 7 and 8. MALP-2 (TLRs 2, 6), Loxoribine
(TLR7), Pam3CSK4 (TLR2), Flagellin (TLR5) all pur-
chased from Invivogen (San Diego, CA), LPSE.coli (TLR4)
and Poly I:C (TLR3) both purchased from Sigma-Aldrich
(St. Louis, MO). CD40-specific CD40L-XL (crosslinked)
was purchased from Alexis Biochemicals (Axxora Corpo-
ration, San Diego, CA).
The MR targeted vaccine is a fusion protein (designated
B11-hCGβ) which consists of a fully human anti-MR
mAb, B11 genetically fused, via its Fc portion, to the hCGβ
subunit of human chorionic gonadotropin as previously
described [30,31].Journal of Translational Medicine 2007, 5:5 http://www.translational-medicine.com/content/5/1/5
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Cytokines and mitogens
Polyclonal B and T cell activators- KLH and PHA, respec-
tively, were obtained from Sigma-Aldrich Chemical Co.
(St. Louis, MO). GM-CSF, IL-4 and IFNα were purchased
from R&D Systems (Minneapolis, MN).
Synthetic peptides
Two synthetic peptides of hCGβ used in this study corre-
spond to previously characterized HLA-A2 restricted T cell
epitopes derived from the following sequence: CPTMTRV-
LQGVLPAL [31]. The peptides TMTRVLQGV (hCGβ AA
60–68) and VLQGVLPAL(hCGβ AA 64–72) were custom
made to >95% purity by Peptidogenic Research (Liver-
more, CA).
HLA typing
HLA typing on peripheral blood lymphocytes was per-
formed either by an HLA reference laboratory affiliated
with the University of Colorado, Denver Health Sciences
Center, Denver, CO (ClinImmune Labs; Aurora, CO)
using a PCR based method or serologically using OneLa-
mbda's (Canoga Park, CA) HLA class I and class II loci typ-
ing trays with the resultant identity being confirmed by
microcytotoxicity assay using ethidium bromide/acridine
orange counterstaining. Normal donors (#s 4, through 8)
and patients (#s 1 through 6) in this study typed HLA-
A*0201.
DC generation, hCGβ antigen uptake, activation and 
phenotyping
PBMCs were isolated from normal donor or cancer
patient blood by density gradient centrifugation of
enriched mononuclear cells. Immature DCs were pre-
pared from PBMCs by incubating 2.5 × 106/ml cells in T-
75 flasks (Corning, NY) containing serum-free X-VIVO-15
medium (Cambrex, Walkersville, MD) to promote adher-
ence of monocytes. Non-adherent cells were decanted and
the adherent cells were washed three times with HBSS to
remove platelets, B and T cells. Fresh X-VIVO-15 medium
supplemented with GM-CSF (25 ng/ml) and IL-4 (50 ng/
ml) was added to the adherent monocytes and on days 5–
6 loosely adherent cells showing DC morphology (den-
drite formation) were gently harvested after incubating
the culture flasks at 4°C for 30 min. Detached DCs were
washed three times in cold HBSS, resuspended at 1 × 106
cells/ml of serum-free AIM-V medium and treated with
B11-hCGβ (10 µg/ml) for 30 minutes at 37°C. For DC
maturation, either non-TLR (CD40L at 20 ng/ml) or TLR-
specific agonists (2, 4, 5, 6, 7 and 8) were added to DC cul-
tures with and without the MR targeted vaccine and incu-
bated at 37°C for 16–18 hours. Cells were washed twice
with cold PBS before staining with FITC or PE conjugated
antibodies specific for CD80, CD83, CD86, HLA-DR and
HLA-ABC (BD Biosciences, CA).
Screening of DC activating agents by cytokine profiling 
and alloT cell responses
Monocyte derived immature DCs were generated from
normal donor PBMCs by differentiation with IL-4 and
GM-CSF as described in the previous section. DC matura-
tion was assessed at two levels: (1) The upregulation of
Th1 priming cytokines and (2) The induction of an MLR-
type response. Such an assessment would indicate
whether the agent was potent enough to drive DC-
dependent proliferative T cell responses via enhanced
expression of allo-HLA and co-stimulatory molecules on
DCs. The concentration of specific TLR activators was used
according to manufacturer's instructions. Monocyte-
derived immature DCs (5 × 103/well) were exposed to dif-
ferent TLR activators as single treatments with or without
the vaccine at 37°C for 16–18 hours. Cell-free superna-
tants were harvested and analyzed in triplicate for a panel
of cytokines and chemokines using both commercial kits
(Proteoplex; EMD BioSciences, St. Louis, MO; Human
Quant I/II, Schleicher-Schuell BioSciences/Whatman,
Inc., Sanford, ME) and cytokine screening services (Allied
Biotech, Human Cytokine Screening Service, (Ijamsville,
MD). The concentration of each cytokine was expressed as
pg/ml. Allogeneic T cell responses were evaluated by the
degree of stimulation as measured by [3H]-thymidine
([3H]-TdR) incorporation using a β-scintillation counter.
Responses of two fold higher relative to no stimulation
controls were considered to be a positive response.
In vitro generation of CTL and Granzyme B release from 
hCGβ-specific T cells
For in vitro stimulation of T cells, the non-adherent frac-
tion of patient PBMCs (herein referred to as PBL) were co-
cultured at 1.0 × 106 cells/ml/well, in 24-well plates with
the antigen-exposed mature autologous DCs at 5 × 104
cells/ml/well (T cell: DC ratio = 20) for 3 to 4 consecutive
weeks in AIM-V media. The cultures were supplemented
with low doses of IL-7 and IL-2 (10 ng/ml each) in the first
week and then maintained 20 ng/ml IL-2 to support the
growth of antigen-activated T cells. Cytokines and media
were changed every 3–4 days.
Five days after the second or third round of weekly re-
stimulation, T cells were harvested and assessed in a cyto-
toxic Granzyme B release assay (GrB-ELISpot kit, Cell Sci-
ences Inc., Canton MA; Ref. 40) as follows: Effector T cells
from patient PBMCs were stimulated with either peptide
pulsed T2 cells, antigen naïve DCs or treated autologous
DCs at a 20:1 ratio directly in the wells of a Granzyme B
(GrB) ELISpot plate for 15–20 hours at 37°C. The plates
were washed and developed as per manufacturer's instruc-
tions (Cell Sciences Corp., Canton, MA). Spot formation
was screened and evaluated by Zellnet Consulting, Inc.
(Fort Lee, NJ). Results are reported as the number of GrB+
spots per 50,000 T cells in the well.Journal of Translational Medicine 2007, 5:5 http://www.translational-medicine.com/content/5/1/5
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Characterization of hCGβ-specific helper T cell responses
Effector T cells (5 × 104/well) derived from patient PBMCs
were stimulated at a 10:1 ratio in 96 well flat bottomed
plates in 200 µl AIM-V medium with autologous DCs that
were either antigen naïve or antigen-treated and matured
with different TLR-activating agents. The cells were co-cul-
tured for a total of 96 hours at 37°C and pulsed with [3H]-
TdR during the last 18 hours (1 µCi/well, Amersham Bio-
Sciences, GE Healthcare, Piscataway, NJ) to measure
uptake of thymidine. Cells were harvested and radioactiv-
ity was detected by scintillation counting (Wallac
Microbeta Jet). Results are reported as mean ± S.D. of sex-
tuplicate wells. Proliferation was also assessed by BrdU
incorporation using a commercial ELISA kit (Roche Diag-
nostics, Nutley, NJ). Proliferation was evaluated using a
Molecular Devices (Sunnyvale, CA) SpectraMax ELISA
plate reader and SoftMax Pro software. To determine the
stimulation index (S.I.), the "cpm" and "O.D." values (in
the 3H-TdR assay and BrdU ELISA, respectively) from DC-
vaccine-stimulated T cell cultures was divided by T cell
cultures stimulated with DCs without vaccine treatment
(control). An S.I. value greater than 2 fold higher than that
in the control was considered a positive response.
Statistical analysis
A two-tailed Student's t test for paired samples was used
for comparison of vaccine only to vaccine plus adjuvant
combination treatments using Microsoft Excel's statistical
analysis tools for Windows NT. A 'p' value of 0.05 or less
was considered to be significant.
Results
hCGβ vaccine-treated DC modulation with selected TLR-
activating ligands
Monocyte-derived DCs were harvested on day 5 and
exposed to every combination of the vaccine (B11-hCGβ)
in conjunction with the ligands specific for the various
TLR (2, 4, 5, 6, 7 and 8) or non-TLR molecules (CD40, IFN
receptor). First, we examined several normal donor DC
samples to optimize experimental conditions which
included a 30 minute exposure to the vaccine at 37°C fol-
lowed by the addition of TLR-specific ligands to DC cul-
tures for further incubation (~18 hours). Cell-free
supernatants were collected thereafter and analyzed by
cytokine multiplex arrays. As shown in Fig. 1a (donor #s
4–8), IL-12p70 produced by DCs in response to adjuvants
poly I:C and R-848 in combination with the vaccine (B11-
hCGβ) was enhanced compared to poly I:C or R-848 treat-
ment alone. Interestingly, DCs from donor #6 showed
equivalent IL-12p70 production DCs treated with vaccine
alone or adjuvant alone and vaccine+ R-848 combination.
R-848 + vaccine treatment of DCs markedly enhanced IL-
12p70 production compared to R-848 treatment alone in
donor #s 4, 5, 7, 8 whereas poly I:C+ vaccine treated DCs
produced IL-12p70 more than poly I:C alone in donors 6,
7 and 8. In all donors tested the relative levels of IL-10 in
the vaccine + poly I:C or vaccine+ R-848 was 3–10 fold
lower compared to that of IL-12p70. E
The possibility that an underlying cross-talk between TLR
and MR signaling pathways might contribute towards a
Th1 T cell polarizing event prompted us to examine the
effect of independently engaging different TLR agonists in
the presence of B11-hCGβ vaccine. As shown in Table 1,
DCs from donor #4 and #5 were considered for extended
TLR-MR activation studies. Thus, DCs that were treated
with TLR-specific ligands with or without the vaccine were
assessed for two opposing cytokines that are representa-
tive of a Th1 response (IL-12p70, a critical regulator of
adaptive immune responses) or a Th2 response (IL-10, an
anti-inflammatory cytokine). DCs were screened for a
cytokine response to various stimuli directed at TLR (2, 3,
4, 5, 6, 7 and 8) and non TLR receptors (CD40, IFN). Data
represented in Table 1 show that the vaccine in combina-
tion with activation signals is consistently contributing to
a Th1 type response (IL-12p70 > IL-10). In the case of
TLR2 stimulation, however, IL-12p70 production is
dampened when MALP-2, but not Pam3CSK4, is used as
the ligand for this receptor suggesting that additional TLRs
(presumably, TLR6) may be involved in attenuating the
TLR2-dependent signaling. For the two adjuvants that
appear to be potentially applicable in the clinic, namely
poly I:C and R-848, combination with vaccine clearly aug-
mented DC-dependent IL-12p70 production compared to
IL-10 suggesting a Th1-bias (p < 0.01 and p < 0.05, respec-
tively). Signaling via TLR-independent pathways such as
those obtained by CD40-CD40L interaction further indi-
cate that antibody targeting of MR may intersect with MAP
kinase pathways via common downstream adaptor mole-
cules which are yet to be characterized.
TLR activation also induces potent Th1 cytokine 
production in patient DCs
To investigate whether the Th1-type modulation observed
above in normal donors (Fig. 1a) can be reproduced in
cancer patients, monocyte-derived DCs from a subset of
cancer patient PBMCs were treated with vaccine in the
absence or presence of TLR agonists. Monocyte-derived
DCs from all three patient demonstrated that activated
TLRs can enhance IL-12p70 cytokine production in con-
cert with MR-targeting. Moreover, these responses appear
to be highly vaccine-specific (i.e. directed to hCGβ com-
ponent of the vaccine) since controls (vaccine-naïve DCs
or DCs exposed to a non-targeted soluble hCGβ), the vac-
cine vehicle (B11) and a isotype-matched control IgG
were not able to induce Th1 cytokines (Fig. 1b). In addi-
tion, DC modulation with poly I:C and R-848 in the
absence of vaccine targeting can still induce IL-12p70, but
the secretion was enhanced with vaccine combined with
TLR activation during DC stimulation. Also, as noted forJournal of Translational Medicine 2007, 5:5 http://www.translational-medicine.com/content/5/1/5
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Vaccine targeting mannose receptor polarizes dendritic cells to a Th1 cytokine phenotype Figure 1
Vaccine targeting mannose receptor polarizes dendritic cells to a Th1 cytokine phenotype. Monocyte-derived 
DCs from normal donor PBMCs (1a) or cancer patients (1b) were treated as described under Methods. (1a) Differential Th1-
type cytokine production by DCs treated separately with vaccine (B11-hCGβ at 10 µg/ml) and TLR activating agents; (1b) Vac-
cine-specific DC-dependent Th1 cytokine induction in cancer patients.
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normal donor DCs, the effect mediated by vaccine only
treated DCs was further augmented by the addition of TLR
3, 7/8 activation signals. As in normal donor DCs, IL-10
production by patient DCs was several fold lower com-
pared to IL-12p70, indicating a dominant polarization to
a Th1 type DC.
Induction of allogeneic response following MR and TLR 
targeting of DCs
In an allogeneic mixed lymphocyte reaction assay, T cells
respond by proliferation to changes in the level of MHC
class I, II and co-stimulatory molecules on the stimulatory
DCs regardless of the antigen being presented. Using nor-
mal donor PBMCs, T cells from one donor were co-cul-
tured with treated DCs from a different donor (HLA-
mismatched at several loci) for 5 days and pulse chased
for the last 18 hours with tritiated thymidine (3H-TdR). As
depicted in Fig. 2, strong proliferative responses were
noted for a variety of DC treatments as shown by
increased uptake of thymidine. However, DCs that
received TLR signaling in the absence of antigen (no vac-
cine) did not induce T cell proliferation to the same extent
(Fig. 2a) as those that were exposed to the vaccine (Fig.
2b). The differential between the two treatments was
apparent in the case of TLR 2, TLR3, TLR 5 and TLR 7-spe-
cific activation suggesting that the vaccine clearly contrib-
utes to the response. Surprisingly, the TLR 7/8 agonist, R-
848-mediated modulation of DCs did not induce a strong
proliferative alloresponse with or without vaccine (Fig.
2c) suggesting that TLRs 7 and 8 expression may be
reduced in monocyte-derived DCs. Stimulation indices
calculated for the different stimuli, as shown in Table 2,
further shows that most TLR-specific stimuli, with the
exception of LPS and R-848 as single agents and R-848
combined with poly I:C, were able to elicit a detectable
allogeneic response when combined with B11-hCGβ vac-
cine.
R-848 can modulate DC surface phenotype independent 
of antigen
The availability of a clinical-grade class of imiquimod, R-
848, that specifically activates TLR7/8 expressing cells
such as human DCs, prompted us to investigate the prop-
erties of this immunomodulatory agent in the context of
MR targeting. Immature monocyte-derived DCs were
treated with a range of doses of R-848, with or without the
B11-hCGβ vaccine for 24 or 48 hours [see Additional files
1 and 2] and stained for maturation/activation markers
CD80, CD83, CD86, HLA-ABC and HLA-DR. The upregu-
lation of DC HLA-DR expression following R-848 treat-
ment (MFI 1807 treated vs. 1324 untreated), CD80 (MFI
447 treated vs. 256 untreated) and CD86 (MFI 447 treated
vs. 265 untreated) was noted with R-848 with or without
the vaccine. In contrast, the expression of HLA-ABC only
marginally changed (MFI 186 treated vs. 171 untreated)
while levels of CD83 did not appear to be particularly
affected by the treatments (MFI 25 treated vs. 24
untreated). These results indicate that DC surface markers
can be sufficiently modulated with R-848 to prime T cell
function which subsequently led to studies on the induc-
tion of autologous T cell responses in patients. The upreg-
ulation of HLA and co-stimulatory markers on DCs using
other TLR activating agents in combination with B11 mAb
has been observed using LPS or Flagellin (unpublished
observations). While the latter observation is consistent
with alloresponses, the lack of T cell effector function in
an autologous setting suggests that signaling via TLR4 or
TLR5 in conjunction with MR signaling may not ade-
quately support Th1 priming as that generally seen with
CD40-CD40L or TLR3 or TLR 7/8 signaling (IL-12p70
induction).
In vitro CTL induction in cancer patients
Since DCs appear to be amenable to modulation with
TLR-activating ligands, it was important to determine
Table 1: Production of Th1-like cytokines by activated DCs
Immature Mo-DC Treatment Donor 4 Donor 5
No vaccine Vaccine No vaccine Vaccine No vaccine Vaccine No vaccine Vaccine
IL-10 IL-10 IL-12p70 IL-12p70 IL-10 IL-10 IL-12p70 IL-12p70
None 43 ± 2 61 ± 10 145 ± 10 498 ± 23 30 ± 4 23 ± 10 115 ± 18 121 ± 11
Activated CD4+ T 46 ± 8 149 ± 3 189 ± 16 154 ± 12 60 ± 15 241 ± 3 234 ± 6 644 ± 6
CD40L XL 45 ± 3 211 ± 21 185 ± 40 4818 ± 18 136 ± 11 513 ± 9 1139 ± 24 1406 ± 6
LPS E.coli 171 ± 16 1041 ± 26 308 ± 11 1588 ± 1 10 415 ± 4 552 ± 11 1089 ± 19 1859 ± 60
Poly I:C * 184 ± 11 307 ± 6 2221 ± 210 8327 ± 240 308 ± 10 475 ± 24 1369 ± 58 2847 ± 36
MALP -2 87 ± 13 125 ± 12 7646 ± 110 169 ± 33 41 ± 12 574 ± 22 1512 ± 26 610 ± 11
Pam3CSK4 28 ± 4 81 ± 11 40 ± 7 430 ± 23 441 ± 22 691 ± 31 644 ± 15 797 ± 18
Flagellin 54 ± 6 26 ± 7 80 ± 30 335 ± 18 1211 ± 20 1406 ± 11 809 ± 11 4110 ± 51
Loxoribine 22 ± 11 72 ± 8 34 ± 16 1141 ± 9 691 ± 13 1106 ± 31 1839 ± 15 4293 ± 15
R-848 ** 12 ± 3 1106 ± 21 43 ± 10 4293 ± 228 667 ± 9 823 ± 11 983 ± 21 2103 ± 121Journal of Translational Medicine 2007, 5:5 http://www.translational-medicine.com/content/5/1/5
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whether antigen-specific cytolytic effector T cells could be
induced in vitro in primary cultures of autologous periph-
eral blood lymphocytes (PBLs) isolated from cancer
patients. DCs were generated from three HLA-A2+ cancer
patients with different cancers (pancreatic, bladder and
colon) and treated as before (vaccine+ R-848+ poly I:C).
The stimulated DCs were co-cultured with autologous
PBLs for 3–4 weeks in the presence of IL-7 and IL-2 as
indicated in the Materials and Methods section. Effector
CTL detection was assessed in a Granzyme-B ELISpot
assay against a panel of DC targets with a T cell: DC ratio
of 20:1. As shown in Figs. 3a–3d, sensitization of pancre-
atic and bladder cancer patient PBMCs to the vaccine-
adjuvant combination generated higher numbers of vac-
cine specific T cells responding to DCs presenting the cog-
nate form of the vaccine but not to controls (DC, DC-
vehicle or DC-soluble hCGβ). The effector response in the
PBMCs of a colon cancer patient (# 3), however, yielded a
broader response to DC targets modulated by different
TLR activators. Additional patients tested (#s 4, 5 and 6)
showed increased CTL responses when stimulated by DCs
exposed to vaccine in combination with both poly I:C and
R-848 compared to vaccine and either agent alone. Over-
all, the data indicate that DC-vaccine can be optimally
modulated with the addition of TL3 and TLR 7/8 activat-
ing ligands (Fig. 3d).
Enhanced epitope-specific CTL response
To ascertain the true specificity of vaccine-specific
responses in the foregoing experiments, two HLA-A2-
binding peptides derived from the hCGβ sequence were
identified (hCGβ 60–68: TMTRVLQGV and hCGβ 64–72:
VLQGVLPAL). Synthetic peptides were loaded at different
concentrations onto a TAP-/- HLA-A2+ T2 cell line which
served as targets. CTL generated in vitro from patient
PBMCs as described before were tested at different effector
to target ratios against peptide-pulsed or non-pulsed T2
targets with K562 cells serving as an HLA class I negative
control. Whereas cytolytic T cells were induced in all three
patients, patients #2 and #3, in particular, recognized
both epitopes equally well while patient #1 responded
less well relative to controls (Fig. 4). CTL thus generated
appeared to be of high affinity since sub-nanomolar con-
centrations of the peptide were sufficient to sensitize T2
targets to CTL-mediated lysis. Enumeration of vaccine-
specific T cells revealed that DC-vaccine combination with
TLR3 and TLR7/8 activation using R-848 and poly I:C
preferentially expanded a higher frequency of CTL precur-
sors (CTLp) in all three patients than R-848 alone. T cell
effector generation with either TLR agent (poly I:C or R-
848) in combination with the vaccine resulted in AICD
(activation-induced cell death) of T cells over a period of
several weeks (usually after second or third re-stimula-
tion). In terms of CTLp frequency with specificity for
hCGβ HLA class I-restricted epitopes presented by non-
professional APCs (autologous PBMCs), responses were
only noted in patient #3 [hCGβ 60–68: 1/400 and hCGβ
64–72: 1/316; see Additional file 3]. The observed varia-
tion in the frequency of GrB+ CTL vis-à-vis antigen pres-
entation by vaccine-pulsed (DCs) or peptide-pulsed APCs
(PBMCs) may be related to DC presentation of multiple
(unknown) epitopes that could contain post-translational
modifications, as also to additional signals required for
complete effector function of CTL only mediated by DCs,
but not PBMCs. These results indicate that CTL not only
recognize whole antigen processed and presented by DC
HLA class I molecules but also a pre-processed form of the
antigen presented by alternate APCs (PBMCs or T2 cells)
thus by-passing antigen processing requirements.
Induction of hCGβ-specific T helper responses
The stimulatory capacity of vaccine-treated patient DCs
modulated by TLRs 3 and 7/8 ligands was next assessed
for induction of helper T lymphocyte (HTL)-dependent
responses in a BrdU incorporation assay. As shown in Fig.
5, effector T lymphocytes from all 6 patients co-cultured
with autologous DCs modulated as described above
appear to proliferate extensively not only when presented
with DC stimulators in a cognate form (R-848+ Poly I:C)
but also when R-848 alone was used for modulation.
Overall the results show that R-848 was not superior to
poly I:C for any donor. In 2/6 donors (#s 1 and 2) the two
agents were equivalent in their immunodulatory effects
on DCs. In other donors (#s 3 and 4), poly I:C was only
slightly better than R-848. For 2/6 donors (#s 5 and 6)
neither adjuvant worked as a single agent. (p < 0.05). The
observed differences in DC response patterns between the
donors are not unexpected due to genetic variability
between individuals. Despite these variabilities two nota-
Table 2: Induction of Allogeneic T cell responses by DC 
modulating agents
DC Treatment TLR specificity No Vaccine S.I. Plus Vaccine S.I.
None - -
+ LPS 4 4.1 4.0
+ Pam3CSK4 2 3.0 5.6
+ Flagellin 5 2.4 4.8
+ MALP-2 2, 6 3.0 5.6
+ Poly IC 3
(Fig. 2a-2b) 3.6 6.0
Fig. 2c 2.4 3.8
+ Loxoribine 7 1.25 4.0
+ R-848 7, 8 2.39 1.85
(Fig. 2c)
+ Poly IC + R-848 3, 7, 8 NT 1.95
(Fig. 2c)
NT-not tested; Stimulation indices derived from allogeneicT cell 
responses in a standard 5-day 3H-TdR incorporation assay. Two 
donors were tested in Figure 2a & 2b and three donors were tested in 
Figure 2c.Journal of Translational Medicine 2007, 5:5 http://www.translational-medicine.com/content/5/1/5
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ble observations can be made. First, particular response
patterns were repeated in unrelated donors (1 and 2; 3
and 4; 5 and 6) and second, it can be seen that for 6/6
donors the combination of R-848 and poly I:C was supe-
rior to single agent treatment suggesting the possibility of
identifying a vaccine and adjuvant combination that can
effectively stimulate DCs in spite of immune system poly-
morphisms. Stimulation indices determined in the differ-
ent donors for their respective treatments also appear to
be consistent with the above findings (Table 3).
Discussion
Despite the fact that dendritic cells have been largely
manipulated ex vivo for use as antigen-presenting vehicles
to deliver peptide vaccines, the approach is restricted to
patients with a desired profile such as the most frequent
HLA type and by the limited number of peptides that can
be used to stably associate with these HLA molecules. To
make DC-based vaccines amenable to a wider cross-sec-
tion of the patient population, vaccines could be designed
to include a whole protein that can be delivered directly in
Induction of alloresponses by MR-targeted vaccine combined with TLR activation Figure 2
Induction of alloresponses by MR-targeted vaccine combined with TLR activation. DCs from normal donor PBMCs 
were untreated (2a, 2c) or treated (2b, 2c) with vaccine (B11-hCGβ at 10 µg/ml) in combination with TLR activating ligands 
and added to allogeneic T cells post incubation at different DC: T cell ratios. T cells were pulsed with [3H]-TdR on day 4 and 
harvested on day 5 to assess incorporation of DNA-associated radioactivity. Experiments were performed in triplicates. Data 
are shown as mean ± S.D. of 2 donor (2a, 2b) and 3 donor samples (2c), respectively.
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vivo with high DC-specific targeting properties. This strat-
egy will not only overcome the current limitation of HLA
type of eligible patients but will also circumvent the need
to identify peptides that bind HLA with high affinity and
eliminate costly DC manipulations ex vivo. Vaccines can
be made more efficacious by providing DC activation sig-
nals in vivo (i.e. adjuvants), an effect that is necessary to
drive a desired immune response. However, since DCs do
exist in different forms (subsets) with varying composi-
tion of Toll-like receptors [17], it would be almost neces-
sary to activate only those DC subsets that bear the
appropriate vaccine and adjuvant receptors (e.g. MR and
TLR). Currently, several approaches are being taken to
identify such adjuvant-vaccine combinations. Given the
challenges that patients bring to the clinic including com-
promised sample quality and quantity, the notion of con-
ducting large scale healthy volunteer in vitro studies and
model systems such as the use of HEK-293 TLR or MR
In vitro induction of CTL responses in cancer patient PBMCs Figure 3
In vitro induction of CTL responses in cancer patient PBMCs. T cells were stimulated with autologous DCs treated as 
described under Methods. Briefly, stimulations were performed once every 8 days for a total of 4 weeks with cytokine addi-
tions- IL-2 and IL-7 (10 ng/ml each) and expanded after the third stimulation using anti-CD3/anti-CD28 beads. Expanded cells 
were harvested on day 14 and restimulated with DC+ vaccine (B11-hCGβ, 10 µg/ml) followed by activation with different 
stimuli (3a-c donor #s 1–3) or R-848 (0.1 µM or 0.3 µg/ml.) and Poly IC (50 µg/ml) added alone or in combination (3d, donor 
#s 4–6). T cells were assayed for effector function on days 5 and 6 post stimulation using the Granzyme B ELISpot assay kit.
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transfectants cell lines to mimic the phenomena in
patients may not readily resolve the pressing issue of find-
ing the right fit between antibody vaccines and TLR-spe-
cific adjuvants.
In this study we have screened commercially available
synthetic ligands as well as ligands purified from natural
sources to trigger selected TLR molecules. Specifically, our
goal was to exploit agents for DC modulation that would
be compatible with antibody-targeted vaccines and be
readily translated to the clinic. To this end, we have
selected monocyte-derived DCs for two reasons- (a) they
most closely resemble their counterparts in the dermis
and the interstitial tissues in terms of their immature state
and expression of MR [39]; and (b) dermis is the route of
administration in an ongoing Phase I study of the B11-
hCGβ vaccine. In addition, proof-of-concept studies in
our laboratory have previously shown that targeting MR
on DCs with human antibodies is an efficient way to
deliver tumor antigens to the HLA class I and II- antigen
presentation pathway for activation of T cells restricted by
these molecules [30,31]. Other studies also have reported
the efficiency of targeting antigens to different C-type
lectins on DCs such as DEC-205 [32] and DC-SIGN [33]
with antibodies and have identified DC activation signals
needed to overcome tolerance.
The experimental strategy was designed to assess the
immune modulation of DCs at three levels- (a) pheno-
typic maturation, i.e. to document changes in surface
expression of activation markers such as HLA, co-stimula-
tory and differentiation antigens; (b) functional matura-
Cytolytic T cell response to vaccine in patient PBMCs includes a high affinity T cell compartment with specificity for two HLA- A2-restricted hCGβ-derived epitopes Figure 4
Cytolytic T cell response to vaccine in patient PBMCs includes a high affinity T cell compartment with specifi-
city for two HLA-A2-restricted hCGβ-derived epitopes. Granzyme B-ELISpot determination of antigen specific T cells 
in three cancer patients shows significant effector function is mediated by CD8+ T cells compared to NK cell activity (K562 
lysis). T cells were assessed for activity in triplicates using peptide-loaded TAP -/- T2 cells in the presence of 3 µg/ml β 2 m in 
AIM-V medium for 3 hours at 37°C before transfer to GrB ELISpot plates for a further 16 hour incubation and processed as 
described under Methods.
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Table 3: Autologous T helper responses to vaccines in cancer patients
Stimulation index
DC treatment Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6
Vaccine only 6 5.7 0.0 0.0 0.0 0.0
R-848 only 5.3 5.9 3.6 0.5 0.5 0.5
Vaccine + R -848 5.8 6.2 0.5 0.0 0.0 0.0
Poly IC only 5 5.9 5 5.8 0.0 0.6
Vaccine + Poly IC 5.8 6.0 4.8 6.0 0.0 0.0
Vaccine + R -848 + Poly IC 9.0 6.2 8.0 9.0 6.5 7.0
T cell lines were derived from 6 different donors (all cancer patients) and generated by in vitro stimulation with autologous DCs. Briefly, DCs were 
first exposed to vaccine (B11-hCGβ) and further activated with R-848 and Poly I:C and T cells added to the mix. Proliferative responses were 
tested in a standard 5-day BrdU incorporation ELISA. Values are relative to unstimulated DCs.
Antigen-specific T helper response is amplified when vaccine-treated DCs are further modulated with R-848 and Poly I:C Figure 5
Antigen-specific T helper response is amplified when vaccine-treated DCs are further modulated with R-848 
and Poly I:C. T cells were processed as described in the legend to Fig. 3. Briefly, responder T cells from six cancer patients 
and autologous DCs were co-cultured at a ratio of 10:1 for 5 days in sextuplicates. Cultures were pulsed with BrdU reagent 
during the last 16 hours after which DNA synthesis was measured by assessing BrdU uptake with a BrdU ELISA kit.
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tion, i.e. measuring levels of cytokine secretion using
conditions established in previous studies with demon-
stration of an allogeneic T cell response; and (c) induction
of effector T cell-mediated immune response, i.e. genera-
tion of antigen-specific CTL and helper T lymphocytes
(HTL). Initial attempts at T cell cultures with the different
TLR activators combined with our mAb vaccine (B11-
hCGβ) revealed that poly I:C and R-848 were the only
agents that were capable of stimulating short-term T cell
cultures. The reasons for the failure of other TLR activators
is not apparent but could be related to the quality of
induced maturation/activation of DCs or tolerizing func-
tions of cytokines per se [42,43]. In addition, studies were
performed with dual TLR activators -poly I:C and R-848 in
combination with vaccine both in normal donors and
patients. At all three levels of assessment, our data satisfy
the above criteria as an optimal way to activate DCs for
effective stimulation of T cells.
In summary, the preferential secretion of Th1-biasing
cytokine IL-12p70 over IL-10, the increase in CTL precur-
sor frequency that is both vaccine- and epitope-specific
and an HTL response with similar specificity strongly sug-
gests that TLRs and MRs may be interacting. Of note is the
observation that MR targeting in the absence of additional
(TLR) signals directly contributes to IL-12p70 and this
response is heightened when poly I:C is added to the mix
and vice versa. R-848 alone can induce IL-12p70 in DCs
but unlike TLR3, which is intimately connected with NF-
κB signaling pathway, R-848 may exert its effect primarily
via type I IFN secretion which, in turn, activates IL-12
genes [44]. Induction of a heightened allogeneic by DCs
has remained the hallmark of activation state of DCs. In
this regard, it was interesting to note that unlike the previ-
ously reported immunomodulatory properties [45], the
use of R-848 its use in the context of our vaccine did not
produce an allogeneic T cell response, presumably owing
to differences in DC generation methods (day 7 or day 8
DCs compared to day 5 or day 6 DCs in this study), higher
concentration of R-848 (8 µg/ml vs. 0.3 µg/ml) and the
use of purified allogeneic T cells. However, in an autolo-
gous setting, the induction of cytokine granule secretion
by CTL was evident (Figs. 3 and 4). Although the direct
modulation of DCs in vivo with R-848 has not been inves-
tigated, the possibility that bystander cells that express
TLRs 7 and 8 could be activated to act in concert with DCs
and Mös and to augment T cell cross-priming [46].
An interesting and important question is whether there is
co-localization of the MR and TLRs in the endocytic path-
way. There is preliminary evidence from co-localization
studies showing that MR was found in association only
with TLR3, but not TLR4, TLR7 or TLR8 (unpublished
observations). It is unclear why there was no detectable
TLR4 staining in mature DCs but it could be related to the
DC maturation pathway [47]. In addition, the activation
of DCs via TLR9 was not pursued in this study since, in
humans, dermal and monocyte-derived DCs do not
express TLR9. Conversely, DCs that express TLR9, such as
plasmacytoid DCs (pDCs) do not express MR and there-
fore, were not suitable for targeting.
In general, the idea of engaging specific TLRs is beneficial
both to augmenting antigen presenting capacity of DCs as
well as sustaining a high avidity effector T cell repertoire.
Although all of the above data consistently show immu-
nopotentiating effects of TLR ligands in augmenting
immunological responses to an MR-targeted vaccine, it is
not certain whether engagement of two independent TLRs
is a requirement in vivo (in human trials). It is important
to consider that the vaccine product would now have
three different entities requiring additional regulatory
hurdles to overcome so as to secure approval for use in
humans. Another consideration is that the inclusion of
TLR activators in vaccine formulations is limited in that
individuals vary in their TLRs owing to genetic polymor-
phisms. This is the case with TLR2 and TLR4 where muta-
tions have been reported [48]. Therefore, caution must be
exercised in deciding which TLRs must be activated since
individuals with TLR deficiencies cannot respond to dan-
ger signals [49].
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